Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Samer Al Hadidi
Study finds ‘substantial’ underrepresentation of Black patients in CAR-T clinical trials
Source/Disclosures Source/Disclosures We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Black patients appeared consistently underrepresented in pivotal clinical trials that led to FDA approval of several chimeric antigen receptor T-cell therapies, according to findings published in JAMA Network Open.
Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma
[Skip to Navigation] April 28, 2022 JAMA Oncol. Published online April 28, 2022.
Melflufen in multiple myeloma: the conclusion matters
In The Lancet Haematology, Fredrik H Schjesvold and colleagues report the results of the OCEAN phase 3 study of melphalan flufenamide (melflufen) plus dexamethasone versus pomalidomide plus dexamethasone; 1 Schjesvold FH Dimopoulos MA Delimpasi S et al. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol.
Treatment Options for Relapsed and Refractory Multiple Myeloma
Recent advances in the treatment of multiple myeloma (MM) have improved patient outcomes,1 though initial therapy is rarely curative and almost all patients with MM ultimately progress. However, the rapidly evolving treatment landscape for relapsed and refractory MM has made choosing the most appropriate therapy a challenge for many oncologists.
Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs
Presented in part at the 55th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, 31 May to 4 June 2019; the Texas Society of Clinical Oncology 2019 Annual Conference, San Antonio, Texas, 14 September 2019; the 2019 Society of Hematologic Oncology Annual Meeting, Houston, Texas, 11 to 14 September 2019; and the San Antonio Breast Cancer Symposium 2019, San Antonio, Texas, 11 to 14 December 2019.
Delayed Adjuvant Chemotherapy and Survival After Lung Cancer Surgery
To the Editor In their recent article in JAMA Oncology, Salazar et al1 found that patients with non–small cell lung cancer treated with delayed chemotherapy, defined as chemotherapy administered after 56 days, had better outcomes, with hazard ratio of 0.664 (95% CI, 0.623-0.707; P?<?.001) compared with patients who received surgery alone. The authors listed multiple valid limitations to their study, including the retrospective nature of the National Cancer Database data that they used.
Timing of Pregnancy and Survival in Women With Breast Cancer
To the Editor Iqbal et al1 reported no survival difference in pregnant compared with nonpregnant women with a breast cancer diagnosis in a recent JAMA Oncology article. The 5-year actuarial survival rate was 97% for women who had pregnancy 6 months or more after diagnosis of breast cancer vs 88% for women with no pregnancy, with age-adjusted hazard ratio of 0.22.1 According to eTable 6 in their study, 53% of the analyzed patients are labeled with unknown tumor size.
Dysphagia lusoria presenting as epigastric pain
A 36-year-old African–American woman with medical history of systemic lupus erythematosus, lupus nephritis, protein S deficiency and recurrent deep venous thrombosis presented to outpatient clinic complaining of epigastric pain associated with nausea, vomiting and unintentional weight loss. Esophagogastroduodenoscopy (EGD) was performed; however, mucosal tear was noted following severe retching. Subsequently, the procedure was terminated. EGD was significant for distal oesophageal obstruction.
Family with clots: antithrombin deficiency
A 44-year-old African-American woman presented to the emergency department with chest pain and shortness of breath of 12?hours prior to presentation. Her medical history includes antithrombin deficiency, recurrent deep venous thrombosis (DVT), recurrent pulmonary emboli, poorly controlled hypertension, diabetes mellitus, asthma, inferior vena cava filter placement, pulmonary hypertension and bipolar disorder.
Aspirin and Cancer Risk
To the Editor Cao et al1 provided an emphasis regarding cancer prevention using aspirin in 2 large prospective cohort studies: the Nurses’ Health Study and Health Professionals Study. Overall cancer risk reduction was minimal, with a relative risk of 0.97 (95% CI, 0.94-0.99). The major benefit was for gastrointestinal cancers, mainly colorectal cancers.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Samer Al
Contact Samer Al, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack